COVID Vaccine Leader Moderna (NASDAQ:MRNA) Eyes 2025 Growth with Vaccine Launches - TipRanks.com
Pharmaceutical and biotechnology company, Moderna’s (NASDAQ:MRNA) CEO Stéphane Bancel stated in a letter to its shareholders that the company’s market share when it comes to COVID-19 vaccines in the U.S. rose to 48% in 2023 from 37% in 2022. In the third quarter of Fiscal 2023, the company saw a…
#stéphanebancel #spikevax #rsv #moderatebuy #holds